Phase 2 N=101 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Broad Solid Tumor
Primary: Number of Participants With Adverse Events — 1; 2; 3; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
Breast Cancer
Primary: Number of Participants With at Least One Treatment-related Adverse Event of Interest — 15; 20 Participants
Phase 2 N=120 Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)
Binge Drinking · HIV
Primary: Binge Drinking Days Per Week — 1.056; 1.722 days per week
Phase 2 N=78 Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain
Metastatic Solid Tumors of Metastatic Disease
Primary: Number of Participants With Skeletal Related Events (SREs) — 10; 1; 29; 38 number of participants
Phase 2 N=20 Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: The Number of Subjects Who Achieve at Least a 30 Percent Decrease in Pain From Baseline in VAS Pain Score Calculated From BPI Questionnaire. — 8 Participants
Phase 2 N=7 Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
Chronic Kidney Diseases
Primary: Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). — -0.009 fat/muscle ratio
Phase 2 N=126 Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone
Chronic Pruritus
Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)
Phase 2 N=16 Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b — -83.07; -79.84; -81.58; -12.91 percent change
Phase 2 N=9 Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Acral Lentiginous Melanoma
Primary: Overall Response Rate (ORR) — 1 participants
Phase 2 N=30 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Acute-graft-versus-host Disease · aGVHD · GVHD
Primary: Number of Treatment Emergent Adverse Events — 4; 17; 9 Participants
Phase 2 N=35 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Advanced Adult Hepatocellular Carcinoma · Advanced Fibrolamellar Carcinoma
Primary: Overall Response Rate — 1; 20; 10; 4 Participants
Phase 2 N=14 Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycocalyx Integrity-Perfused Boundary Region — -0.0057 micrometers (mcm)
Phase 2 N=28 Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Locally Advanced Pancreatic Carcinoma(LAPC)
Primary: Disease Control Rate (DCR) — 73 Percentage of participants
Phase 2 N=16 Semaglutide Use in Elderly Obese Patients
Obesity · Aging
Primary: Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio — 1.04; 1.0; 0.96; 0.99 Arbitrary units (ratio)
Phase 2 N=100 Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-induced Nausea and Vomiting
Primary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3…